04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
19:52 , Oct 13, 2017 |  BC Week In Review  |  Company News

AbbVie acquires options to Turnstone immunotherapies

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
22:18 , Oct 10, 2017 |  BC Extra  |  Company News

AbbVie, Turnstone in oncolytic virus deal

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
16:28 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the Journal of Clinical Oncology , researchers at NIH's NCI and colleagues reported that a major histocompatibility complex (MHC) class II-restricted melanoma-associated antigen A3 (MAGEA3)-targeted T cell receptor (TCR) T...
20:51 , Aug 17, 2017 |  BC Extra  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the Journal of Clinical Oncology , researchers at NIH's NCI and colleagues reported that a melanoma-associated antigen A3 ( MAGEA3 )-targeted T cell receptor (TCR) T cell therapy from Kite...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
20:05 , May 19, 2017 |  BC Week In Review  |  Clinical News

Turnstone begins Phase I/II NSCLC trial of viral therapy

Turnstone Biologics Inc. (Ottawa, Ontario) began the Phase I/II Sandpiper trial of its adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 (MG1-MAGEA3) plus Keytruda pembrolizumab to treat metastatic non-small cell lung cancer (NSCLC)...
19:57 , Jan 13, 2017 |  BC Week In Review  |  Company News

Kite, Fosun deal

Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, axicabtagene ciloleucel (KTE-C19), in China. The JV may also...